Edit Module

Novartis Launches 3-Day Feline NSAID



Published:

Novartis Animal Health launched Onsior (robenacoxib) tablets, a three-day non-steroidal anti-inflammatory drug for postoperative cats, the Greensboro, N.C., company reported today.

The drug is indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration. It is the first multidose oral NSAID to be approved for cats, Novartis reported.

The drug’s short blood half-life causes the active ingredient to be quickly eliminated from the blood while persisting longer at the site of inflamed tissue, allowing for once-a-day administration for up to three days, the company reported.

Side effects observed during a clinical field trial and six-month safety study included surgical site bleeding, infected surgery sites, lethargy, vomiting and inappetence.

The drug is indicated for cats weighing 5.5 pounds or heavier and at least 6 months old for a maximum of three days. The drug should not be used in cats that have a hypersensitivity to robenacoxib or known intolerance to NSAIDs and should not be administered in conjunction with any other oral or injectable NSAID or corticosteroid, according to Novartis.

 <HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

The Idea Competition Sparks Veterinary Student Innovation

One contest leads three student teams to win prizes to fund ongoing development of their new industry product concepts.

Zoetis, AAVMC Announce 315 Scholarships to Vet Students

The winners of the 2017 Zoetis Veterinary Student Scholarship Program were presented at the 2017 Student American Veterinary Medical Association.

IDEXX Initiative Seeks to Minimize Radiation Risks

Lower the Dose aims to help the veterinary industry improve in-practice radiation safety.

Add your comment:
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module